Key Record Dates Identifier: NCT04303169
Brief Title: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

First Submitted : March 9, 2020
First Submitted that Met QC Criteria : March 9, 2020
First Posted : March 10, 2020

Last Update Submitted that Met QC Criteria : September 23, 2021
Last Update Posted : September 24, 2021 (Estimate)